Fiche publication
Date publication
novembre 2025
Journal
Molecular metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PAIS DE BARROS Jean-Paul
,
Pr MASSON David
Tous les auteurs :
Taradeh M, Hardy LM, Dahik VD, Lhomme M, Wang H, Reydellet C, Materne C, Kc P, Bun E, Clemessy M, Pais-De-Barros JP, Galier S, Frisdal E, Durand H, Ponnaiah M, El Khoury P, Villard EF, Lesnik P, Gallo A, Kappeler L, Giral P, Bruckert E, Masson D, Guerin M, Kontush A, Guillas I, Le Goff W
Lien Pubmed
Résumé
Low plasma high-density lipoprotein (HDL)-cholesterol levels are associated with increased risk of atherosclerotic cardiovascular disease (ASCVD), potentially reflecting impaired antiatherogenic HDL functions. These latter are strongly influenced by the HDL phospholipidome, which is frequently altered in ASCVD patients. Several studies reported that plasma levels of phosphatidylethanolamine (PE) species, particularly PE (36:5), were positively associated with ASCVD, but the underlying mechanisms remain unclear. Plasma PE (36:5) exists as eicosapentaenoic (EPA)-PE and arachidonic acid (ARA)-PE, with the latter predominating in ASCVD. This study investigated whether the association of PE (36:5) with ASCVD might result from an impairment of the antiatherogenic functions of HDL.
Mots clés
Atheroprotective functions of HDL, High-density lipoproteins (HDL), arachidonic acid, atherosclerosis, eicosapentaenoic acid, phosphatidylethanolamine
Référence
Mol Metab. 2025 11 15;:102281
